新诺威(300765.SZ)：控股子公司度普利尤单抗注射液获得药物临床试验批准通知书

Core Viewpoint - The company XinNuoWei (300765.SZ) announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, which will commence shortly [1] Group 1 - Dupilumab injection is a recombinant fully human monoclonal antibody drug targeting IL-4Rα, developed as a biosimilar to Dupixent [1] - The drug is classified under Category 3.3 for therapeutic biological products and is intended for the treatment of moderate to severe atopic dermatitis in adults [1] - The research and development of this product adhere to the relevant guidelines for biosimilars, with pharmaceutical and non-clinical research results indicating high similarity in quality, safety, and efficacy compared to the reference drug [1]